규제 업데이트

The FDA approved ANDA080279 for a 5 mg oral prednisone tablet submitted by Inwood Labs; the product is listed as discontinued.

FDA records show SOLVAY's oral tablet TRANMEP, containing 400 mg meprobamate, is listed as discontinued under application ANDA084369.

The FDA has approved ANDA 084872 for a 25 mg oral tablet of Meclizine Hydrochloride marketed by BUNDY, with a discontinued marketing status.

The FDA has approved ANDA080630 for a 25 mg oral tablet of cortisone acetate, submitted by IVAX Sub Teva Pharm, with approval dated Jan 3 1972.

Quantum Pharmics filed ANDA 088972 for an oral tablet combining 50 mg butalbital, 325 mg aspirin, and 40 mg caffeine; the product is listed as discontinued.

The FDA database shows an ANDA (ANDA088660) for an oral tablet of thioridazine hydrochloride 25 mg submitted by West Ward, currently marked as discontinued.

The FDA has approved Mylan Pharmaceuticals' sumatriptan succinate tablets (25 mg, 50 mg, 100 mg) under ANDA 077744, with multiple labeling submissions recorded.

FDA has approved ANDA083386 for chlorpromazine hydrochloride tablets (10 mg) manufactured by Upsher‑Smith Laboratories, listed as a prescription oral drug.

The FDA has processed application ANDA084026 for Watson Labs' oral chlorothiazide 500 mg tablet, currently listed as discontinued.

The FDA has approved ANDA078845 for a 600 mg oral linezolid tablet marketed by Rising Pharma Holdings, Inc.

FDA approved ANDA085911 for an oral tablet containing 5 mg oxycodone and 500 mg acetaminophen, submitted by Bristol Myers Squibb; the product is listed as discontinued.

The FDA approved ANDA077053 for Ribavirin 200 mg oral tablets, sponsored by Heritage Pharma Avet. The product is listed with a discontinued marketing status.